Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Hopkins

Showing results (741-750 of 856) with videos related to

Pageof 86
Sort By:
Sexually Transmitted Diseases|August 26, 2009
Innovative resources could help improve partner notification for chlamydia in primary careJade E Bilardi, Carol A Hopkins, Christopher K Fairley, et al.
Scientific Reports|August 29, 2018
Exercise in pregnancy: 1-year and 7-year follow-ups of mothers and offspring after a randomized controlled trialValentina Chiavaroli, Sarah A Hopkins, José G B Derraik, et al.
Molecular Cancer Research : MCR|November 16, 2018
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone MarrowTodd A Hopkins, William B Ainsworth, Paul A Ellis, et al.
Critical Care (London, England)|May 16, 2020
Neurally adjusted ventilatory assist versus pressure support ventilation: a randomized controlled feasibility trial performed in patients at risk of prolonged mechanical ventilationDaniel J Hadfield, Louise Rose, Fiona Reid, et al.
Antiviral Chemistry & Chemotherapy|January 6, 1999
The design, synthesis and properties of highly potent and selective inhibitors of herpes simplex virus types 1 and 2 thymidine kinaseJ A Martin, G J Thomas, J H Merrett, et al.
BMC Infectious Diseases|September 21, 2010
Better than nothing? Patient-delivered partner therapy and partner notification for chlamydia: the views of Australian general practitionersNatasha L Pavlin, Rhian M Parker, Anna K Piggin, et al.
Bioorganic & Medicinal Chemistry Letters|April 21, 2010
Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpesvirus antivirals with improved aqueous solubilityJames A Nieman, Sajiv K Nair, Steven E Heasley, et al.
Journal of Laser Applications|May 27, 1999
Ultrashort laser pulse bioeffects and safetyB A Rockwell, D X Hammer, R A Hopkins, et al.
Molecular Cancer Research : MCR|July 29, 2015
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP InhibitorsTodd A Hopkins, Yan Shi, Luis E Rodriguez, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2002
Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitorsNancee L Oien, Roger J Brideau, Todd A Hopkins, et al.
Pageof 86

Showing results (741-750 of 856) with videos related to

Sort By:
Pageof 86
Sexually Transmitted Diseases|August 26, 2009
Innovative resources could help improve partner notification for chlamydia in primary careJade E Bilardi, Carol A Hopkins, Christopher K Fairley, et al.
Scientific Reports|August 29, 2018
Exercise in pregnancy: 1-year and 7-year follow-ups of mothers and offspring after a randomized controlled trialValentina Chiavaroli, Sarah A Hopkins, José G B Derraik, et al.
Molecular Cancer Research : MCR|November 16, 2018
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone MarrowTodd A Hopkins, William B Ainsworth, Paul A Ellis, et al.
Critical Care (London, England)|May 16, 2020
Neurally adjusted ventilatory assist versus pressure support ventilation: a randomized controlled feasibility trial performed in patients at risk of prolonged mechanical ventilationDaniel J Hadfield, Louise Rose, Fiona Reid, et al.
Antiviral Chemistry & Chemotherapy|January 6, 1999
The design, synthesis and properties of highly potent and selective inhibitors of herpes simplex virus types 1 and 2 thymidine kinaseJ A Martin, G J Thomas, J H Merrett, et al.
BMC Infectious Diseases|September 21, 2010
Better than nothing? Patient-delivered partner therapy and partner notification for chlamydia: the views of Australian general practitionersNatasha L Pavlin, Rhian M Parker, Anna K Piggin, et al.
Bioorganic & Medicinal Chemistry Letters|April 21, 2010
Modifications of C-2 on the pyrroloquinoline template aimed at the development of potent herpesvirus antivirals with improved aqueous solubilityJames A Nieman, Sajiv K Nair, Steven E Heasley, et al.
Journal of Laser Applications|May 27, 1999
Ultrashort laser pulse bioeffects and safetyB A Rockwell, D X Hammer, R A Hopkins, et al.
Molecular Cancer Research : MCR|July 29, 2015
Mechanistic Dissection of PARP1 Trapping and the Impact on In Vivo Tolerability and Efficacy of PARP InhibitorsTodd A Hopkins, Yan Shi, Luis E Rodriguez, et al.
Antimicrobial Agents and Chemotherapy|February 19, 2002
Broad-spectrum antiherpes activities of 4-hydroxyquinoline carboxamides, a novel class of herpesvirus polymerase inhibitorsNancee L Oien, Roger J Brideau, Todd A Hopkins, et al.
Pageof 86